Sentiment-Signal
34,3
Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
44.4
1 neu, 0 erhöht, -7717324K $ netto
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 28.10.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appo |
Stammdaten
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
Unternehmen & Branche
| Name | Jazz Pharmaceuticals plc |
|---|---|
| Ticker | JAZZ |
| CIK | 0001232524 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 0G5087110 |
|---|---|
| ISIN | US0G50871102 |
| Typ | Common Stock |
| Marktkapitalisierung | 12,26 Mrd. USD |
| Beta | 0,23 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 4,267,586,000 | -356,148,000 | -5.84 | 11,659,340,000 | 4,318,584,000 |
| 2025-09-30 | 10-Q | 1,126,107,000 | 251,412,000 | 4.08 | 11,356,485,000 | 3,959,030,000 |
| 2025-06-30 | 10-Q | 1,045,712,000 | -718,470,000 | -11.74 | 10,944,141,000 | 3,706,359,000 |
| 2025-03-31 | 10-Q | 897,841,000 | -92,541,000 | -1.52 | 11,534,682,000 | 4,174,891,000 |
| 2024-12-31 | 10-K | 4,068,950,000 | 560,120,000 | 8.65 | 12,012,257,000 | 4,093,756,000 |
| 2024-09-30 | 10-Q | 1,054,969,000 | 215,055,000 | 3.42 | 12,255,716,000 | 4,171,067,000 |
| 2024-06-30 | 10-Q | 1,023,825,000 | 168,568,000 | 2.49 | 11,361,868,000 | 3,762,599,000 |
| 2024-03-31 | 10-Q | 901,983,000 | -14,618,000 | -0.23 | 11,327,075,000 | 3,696,461,000 |
| 2023-12-31 | 10-K | 3,834,204,000 | 414,832,000 | 6.10 | 11,393,359,000 | 3,736,997,000 |
| 2023-09-30 | 10-Q | 972,140,000 | 146,820,000 | 2.14 | 11,204,065,000 | 3,489,373,000 |
| 2023-06-30 | 10-Q | 957,317,000 | 104,438,000 | 1.52 | 11,260,540,000 | 3,525,675,000 |
| 2023-03-31 | 10-Q | 892,812,000 | 69,420,000 | 1.04 | 11,047,125,000 | 3,335,041,000 |
| 2022-12-31 | 10-K | 3,659,374,000 | -224,060,000 | -3.58 | 10,835,255,000 | 3,085,734,000 |
| 2022-09-30 | 10-Q | 940,652,000 | -19,648,000 | -0.31 | 10,384,667,000 | 2,745,194,000 |
| 2022-06-30 | 10-Q | 932,878,000 | 34,665,000 | 0.55 | 11,200,133,000 | 3,200,781,000 |
| 2022-03-31 | 10-Q | 813,721,000 | 1,647,000 | 0.03 | 11,768,917,000 | 3,608,487,000 |
| 2021-12-31 | 10-K | 3,094,238,000 | -329,668,000 | -5.52 | 12,298,639,000 | 3,965,191,000 |
| 2021-09-30 | 10-Q | 838,115,000 | -52,833,000 | -0.86 | 12,478,152,000 | 3,938,477,000 |
| 2021-06-30 | 10-Q | 751,811,000 | -363,316,000 | -6.11 | 13,212,993,000 | 4,131,490,000 |
| 2021-03-31 | 10-Q | 607,581,000 | 121,832,000 | 2.09 | 6,756,470,000 | 3,797,689,000 |
Fondsaktivität (Vorquartalsvergleich)
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | 5,917,142 | 0 | 5,917,142 | 1,005,914,140 | Neu | +100,0% | |
| BlackRock, Inc. | 5,451,241 | 0 | 5,451,241 | 926,710,907 | Neu | +100,0% | |
| Capital World Investors | 2,666,602 | 0 | 2,666,602 | 453,322,340 | Neu | +100,0% | |
| DIMENSIONAL FUND ADVISORS LP | 2,623,303 | 0 | 2,623,303 | 445,964,615 | Neu | +100,0% | |
| STATE STREET CORP | 1,837,793 | 0 | 1,837,793 | 312,424,810 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 1,818,911 | 0 | 1,818,911 | 309,214,909 | Neu | +100,0% | |
| AMERIPRISE FINANCIAL INC | 1,521,090 | 0 | 1,521,090 | 258,585,300 | Neu | +100,0% | |
| MILLENNIUM MANAGEMENT LLC | 1,218,211 | 0 | 1,218,211 | 207,095,870 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 1,197,236 | 0 | 1,197,236 | 203,571,188 | Neu | +100,0% | |
| Swedbank AB | 1,102,974 | 0 | 1,102,974 | 187,505,580 | Neu | +100,0% | |
| JPMORGAN CHASE & CO | 1,044,642 | 0 | 1,044,642 | 177,589,245 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 915,144 | 0 | 915,144 | 155,574,465 | Neu | +100,0% | |
| AQR CAPITAL MANAGEMENT LLC | 877,267 | 0 | 877,267 | 149,135,332 | Neu | +100,0% | |
| RENAISSANCE TECHNOLOGIES LLC | 836,774 | 0 | 836,774 | 142,251,580 | Neu | +100,0% | |
| FMR LLC | 800,925 | 0 | 800,925 | 136,157,167 | Neu | +100,0% | |
| MORGAN STANLEY | 639,179 | 0 | 639,179 | 108,660,659 | Neu | +100,0% | |
| Allianz Asset Management GmbH | 598,832 | 0 | 598,832 | 101,801,440 | Neu | +100,0% | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 547,743 | 0 | 547,743 | 93,116,310 | Neu | +100,0% | |
| Qube Research & Technologies Ltd | 500,486 | 0 | 500,486 | 85,082,620 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 476,871 | 0 | 476,871 | 81,068,070 | Neu | +100,0% | |
| UBS Group AG | 472,952 | 0 | 472,952 | 80,401,840 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 424,290 | 0 | 424,290 | 72,129,300 | Neu | +100,0% | |
| GOLDENTREE ASSET MANAGEMENT LP | 420,341 | 0 | 420,341 | 71,337,490 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 404,320 | 0 | 404,320 | 68,734,400 | Neu | +100,0% | |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | 396,877 | 0 | 396,877 | 67,469,300 | Neu | +100,0% | |
| Boston Trust Walden Corp | 393,911 | 0 | 393,911 | 66,964,870 | Neu | +100,0% | |
| SOUTH PLAINS FINANCIAL, INC. | 386 | 0 | 386 | 65,620,000 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 371,007 | 0 | 371,007 | 63,071,190 | Neu | +100,0% | |
| AMERICAN CENTURY COMPANIES INC | 291,359 | 0 | 291,359 | 49,531,030 | Neu | +100,0% | |
| Vestal Point Capital, LP | 290,000 | 0 | 290,000 | 49,300,000 | Neu | +100,0% | |
| Rockefeller Capital Management L.P. | 265,056 | 0 | 265,056 | 45,059,666 | Neu | +100,0% | |
| BARCLAYS PLC | 254,012 | 0 | 254,012 | 43,182,040 | Neu | +100,0% | |
| VICTORY CAPITAL MANAGEMENT INC | 249,678 | 0 | 249,678 | 42,445,260 | Neu | +100,0% | |
| Saturn V Capital Management LP | 248,070 | 0 | 248,070 | 42,171,900 | Neu | +100,0% | |
| BANK OF MONTREAL /CAN/ | 223,321 | 0 | 223,321 | 37,964,570 | Neu | +100,0% | |
| D. E. Shaw & Co., Inc. | 199,302 | 0 | 199,302 | 33,881,340 | Neu | +100,0% | |
| Invesco Ltd. | 191,296 | 0 | 191,296 | 32,520,320 | Neu | +100,0% | |
| WEDGE CAPITAL MANAGEMENT L L P/NC | 188,878 | 0 | 188,878 | 32,109,260 | Neu | +100,0% | |
| JANE STREET GROUP, LLC | 187,210 | 0 | 187,210 | 31,825,700 | Neu | +100,0% | |
| Pictet Asset Management Holding SA | 184,696 | 0 | 184,696 | 31,486,667 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 183,877 | 0 | 183,877 | 31,259,090 | Neu | +100,0% | |
| RAYMOND JAMES FINANCIAL INC | 177,336 | 0 | 177,336 | 30,186,722 | Neu | +100,0% | |
| Quantinno Capital Management LP | 174,358 | 0 | 174,358 | 29,640,868 | Neu | +100,0% | |
| PERCEPTIVE ADVISORS LLC | 170,000 | 0 | 170,000 | 28,900,000 | Neu | +100,0% | |
| RHUMBLINE ADVISERS | 158,234 | 0 | 158,234 | 26,899,780 | Neu | +100,0% | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 148,323 | 0 | 148,323 | 25,214,910 | Neu | +100,0% | |
| DEUTSCHE BANK AG\ | 140,286 | 0 | 140,286 | 23,848,620 | Neu | +100,0% | |
| Schonfeld Strategic Advisors LLC | 139,217 | 0 | 139,217 | 23,666,890 | Neu | +100,0% | |
| ExodusPoint Capital Management, LP | 137,550 | 0 | 137,550 | 23,383,500 | Neu | +100,0% | |
| PRINCIPAL FINANCIAL GROUP INC | 130,597 | 0 | 130,597 | 22,201,490 | Neu | +100,0% |
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | COZADD BRUCE C | Director | Open Market Sale | -2,292 | 190.94 | -437,630.58 | -47,0% | |
| 2026-04-01 | COZADD BRUCE C | Director | Open Market Sale | -24 | 191.74 | -4,601.87 | -0,5% | |
| 2026-04-01 | COZADD BRUCE C | Director | Open Market Sale | -3,684 | 190.22 | -700,777.85 | -75,3% | |
| 2026-03-09 | Carr Patricia | Officer, SVP, Chief Accounting Officer | Open Market Sale | -1,287 | 182.94 | -235,443.78 | -25,3% | |
| 2026-03-03 | COZADD BRUCE C | Director | Open Market Sale | -3,159 | 186.09 | -587,843.46 | -63,2% | |
| 2026-03-03 | COZADD BRUCE C | Director | Open Market Sale | -2,608 | 186.73 | -487,002.27 | -52,3% | |
| 2026-03-03 | COZADD BRUCE C | Director | Open Market Sale | -233 | 187.84 | -43,767.75 | -4,7% | |
| 2026-02-27 | Carr Patricia | Officer, SVP, Chief Accounting Officer | Open Market Sale | -1,117 | 190.91 | -213,243.45 | -22,9% | |
| 2026-02-27 | RIEDEL NORBERT G | Director | Open Market Sale | -3,415 | 192.00 | -655,680.00 | -70,5% | |
| 2026-02-26 | Patil Neena M | Officer, EVP & Chief Legal Officer | Open Market Sale | -1,784 | 191.88 | -342,311.96 | -36,8% | |
| 2026-02-26 | Patil Neena M | Officer, EVP & Chief Legal Officer | Open Market Sale | -1,061 | 190.00 | -201,593.71 | -21,7% | |
| 2026-02-26 | Patil Neena M | Officer, EVP & Chief Legal Officer | Open Market Sale | -1,009 | 192.79 | -194,526.62 | -20,9% | |
| 2026-02-26 | Patil Neena M | Officer, EVP & Chief Legal Officer | Open Market Sale | -875 | 192.07 | -168,056.96 | -18,1% | |
| 2026-02-26 | Patil Neena M | Officer, EVP & Chief Legal Officer | Open Market Sale | -549 | 190.80 | -104,747.17 | -11,3% | |
| 2026-02-26 | Patil Neena M | Officer, EVP & Chief Legal Officer | Open Market Sale | -197 | 193.60 | -38,138.85 | -4,1% | |
| 2026-02-26 | Carr Patricia | Officer, SVP, Chief Accounting Officer | Open Market Sale | -1,253 | 194.11 | -243,222.21 | -26,1% | |
| 2026-02-26 | Henderson Mary Elizabeth | Officer, SVP, Technical Operations | Open Market Sale | -5,343 | 194.49 | -1,039,134.42 | -111,7% | |
| 2026-02-26 | Patil Neena M | Officer, EVP & Chief Legal Officer | Open Market Sale | -16,602 | 192.53 | -3,196,334.91 | -343,5% | |
| 2026-02-26 | Patil Neena M | Officer, EVP & Chief Legal Officer | Open Market Sale | -15,555 | 190.28 | -2,959,806.96 | -318,1% | |
| 2026-02-26 | Patil Neena M | Officer, EVP & Chief Legal Officer | Open Market Sale | -11,529 | 191.65 | -2,209,480.97 | -237,5% | |
| 2026-02-26 | Patil Neena M | Officer, EVP & Chief Legal Officer | Open Market Sale | -3,523 | 193.58 | -681,993.26 | -73,3% | |
| 2026-02-26 | Patil Neena M | Officer, EVP & Chief Legal Officer | Open Market Sale | -2,916 | 189.81 | -553,490.92 | -59,5% | |
| 2025-12-09 | Henderson Mary Elizabeth | Officer, SVP, Technical Operations | Open Market Sale | -2,238 | 169.51 | -379,365.62 | -40,8% | |
| 2025-12-05 | Carr Patricia | Officer, SVP, Chief Accounting Officer | Open Market Sale | -4,500 | 171.20 | -770,405.40 | -82,8% | |
| 2025-12-05 | Carr Patricia | Officer, SVP, Chief Accounting Officer | Open Market Sale | -160 | 171.11 | -27,377.60 | -2,9% | |
| 2025-11-26 | COZADD BRUCE C | Director | Open Market Sale | -30,487 | 178.06 | -5,428,567.05 | -583,4% | |
| 2025-11-26 | COZADD BRUCE C | Director | Open Market Sale | -507 | 179.79 | -91,154.70 | -9,8% | |
| 2025-11-26 | COZADD BRUCE C | Director | Open Market Sale | -8,380 | 179.23 | -1,501,943.21 | -161,4% | |
| 2025-11-26 | COZADD BRUCE C | Director | Open Market Sale | -38,126 | 177.27 | -6,758,672.27 | -726,4% | |
| 2025-11-20 | McSharry Heather Ann | Director | Open Market Sale | -3,415 | 177.78 | -607,126.55 | -65,2% | |
| 2025-11-18 | Carr Patricia | Officer, SVP, Chief Accounting Officer | Open Market Sale | -5,250 | 182.07 | -955,867.50 | -102,7% | |
| 2025-11-18 | Carr Patricia | Officer, SVP, Chief Accounting Officer | Open Market Sale | -69 | 181.66 | -12,534.54 | -1,3% | |
| 2025-11-18 | Winningham Rick E | Director | Open Market Sale | -5,500 | 180.86 | -994,728.35 | -106,9% | |
| 2025-11-18 | COZADD BRUCE C | Director | Open Market Sale | -8,382 | 180.88 | -1,516,131.13 | -162,9% | |
| 2025-11-18 | COZADD BRUCE C | Director | Open Market Sale | -5,517 | 181.81 | -1,003,071.15 | -107,8% | |
| 2025-11-18 | COZADD BRUCE C | Director | Open Market Sale | -3,384 | 180.09 | -609,410.69 | -65,5% | |
| 2025-11-18 | COZADD BRUCE C | Director | Open Market Sale | -717 | 182.60 | -130,924.85 | -14,1% | |
| 2025-11-17 | Iannone Robert | Officer, EVP, Global Head of R&D & CMO | Open Market Sale | -7,159 | 168.26 | -1,204,573.34 | -129,5% | |
| 2025-10-03 | COZADD BRUCE C | Director | Open Market Sale | -3,500 | 140.00 | -490,000.00 | -52,7% | |
| 2025-10-01 | COZADD BRUCE C | Director | Open Market Sale | -2,000 | 131.78 | -263,560.00 | -28,3% | |
| 2025-09-02 | COZADD BRUCE C | Director | Open Market Sale | -3,000 | 127.23 | -381,690.00 | -41,0% | |
| 2025-09-02 | COZADD BRUCE C | Director | Open Market Sale | -3,000 | 130.00 | -390,000.00 | -41,9% | |
| 2025-08-01 | COZADD BRUCE C | Director, Officer, Chairman & CEO | Open Market Sale | -1,000 | 113.21 | -113,210.00 | -12,2% | |
| 2025-07-01 | COZADD BRUCE C | Director, Officer, Chairman & CEO | Open Market Sale | -500 | 105.26 | -52,630.00 | -5,7% | |
| 2025-07-01 | COZADD BRUCE C | Director, Officer, Chairman & CEO | Open Market Sale | -500 | 110.00 | -55,000.00 | -5,9% | |
| 2025-06-03 | COZADD BRUCE C | Director, Officer, Chairman & CEO | Open Market Sale | -500 | 110.00 | -55,000.00 | -5,9% | |
| 2025-06-02 | COZADD BRUCE C | Director, Officer, Chairman & CEO | Open Market Sale | -500 | 107.90 | -53,950.00 | -5,8% | |
| 2025-05-12 | Mulligan Seamus | Director | Open Market Purchase | 1,621 | 103.00 | 166,961.54 | +17,9% | |
| 2025-05-09 | Mulligan Seamus | Director | Open Market Purchase | 19,216 | 98.91 | 1,900,677.62 | +204,3% | |
| 2025-05-09 | Mulligan Seamus | Director | Open Market Purchase | 80,684 | 98.10 | 7,915,471.55 | +850,7% | |
| 2025-05-09 | Mulligan Seamus | Director | Open Market Purchase | 100 | 99.71 | 9,971.00 | +1,1% | |
| 2025-05-02 | COZADD BRUCE C | Director, Officer, Chairman & CEO | Open Market Sale | -500 | 120.00 | -60,000.00 | -6,4% | |
| 2025-05-01 | COZADD BRUCE C | Director, Officer, Chairman & CEO | Open Market Sale | -1,000 | 116.35 | -116,350.00 | -12,5% |
Top-Fondshalter
Stand: 31.03.2026
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| Parrish Capital LLC | 3,448 | 651,844 | 100.00 |